Got a good line of products, but the share price seem to go down , could it be due to the weak us dollar.

HARRYCAT, you forgot to mention the Drug-failure...hit sp 16%
Q. Is this a Buying Opportunity (Yield ~4%)....or wait and see if it falls further....as the lower TO on existing products is factored-in. This must be a grim time for LT investors have seen the Stock rise from £40 to ~£50 since only Dec.2016( That's +25% in 8 Months !).
- Presumably in the hope that replacement Drug-products will offset the loss of Patent-protection, due to expiry. Now it's not-so there could be further fall from £43 to £40....
EDIT ( 28July2017)- cynic....it's always been "too expensive" for me... and recent fall hardly changes that..... Maybe at £20 I would want some, for the LT revenue, assuming some drug-replacement will occur in time. Ut's human nature for Div-Chiefs to praise themselves for current products....whereas they should be attentive to 10-years on....

this is just one of the drugs in AZN's pipeline
though it's not a stock i have followed, today's fall looks more like a buying opp than the time to jump ship

19/04/2018

Interesting

--=-=-=

AstraZeneca lung cancer drug Tagrisso gets FDA approval
StockMarketWire.com
AstraZeneca said Thursday the US Food and Drug Administration approved its lung cancer treatment Tagrisso for the first-line treatment of patients with metastatic non-small cell lung cancer.

The approval comes after the results of the phase III FLAURA trial, showed Tagrisso met the primary endpoint.

'Today's FDA approval of Tagrisso in the 1st-line setting is an exciting milestone for patients and our company. Tagrisso delivered unprecedented medianprogression-free survival data across all pre-specified patient subgroups, including patients with or without CNS metastases, and could prolong the lives of more patients without their tumours growing or spreading,' said Dave Fredrickson, Executive Vice President, Head of the Oncology Business Unit at AstraZeneca.

Broker Forecast - Jefferies International issues a broker note on AstraZeneca PLC
BFN
Jefferies International today downgrades its investment rating on AstraZeneca PLC (LON:AZN) to hold (from buy) and cut its price target to 5975p (from 6200p).

Story provided by StockMarketWire.com

Broker Forecasts data provided by www.sharesmagazine.co.uk

-=-=-=-=-=

And the price goes down.